Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.7.0.1
Commitments and Contingencies (Details)
$ in Thousands
Jun. 30, 2017
USD ($)
Commencement Of Phase II Study For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities $ 200
Commencement Of Phase III Study For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities 250
Filing Of a New Drug Application For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities 400
Receipt Of Market Approval For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities $ 500